National Academies Press: OpenBook

HIV Screening of Pregnant Women and Newborns (1991)

Chapter: Appndix B: Cost and Probability Assumptions Used in Cost-Effectiveness Analysis of Prenatal HIV Screening

« Previous: Appendix A: The Conference: Program and Summary
Suggested Citation:"Appndix B: Cost and Probability Assumptions Used in Cost-Effectiveness Analysis of Prenatal HIV Screening." Institute of Medicine. 1991. HIV Screening of Pregnant Women and Newborns. Washington, DC: The National Academies Press. doi: 10.17226/1746.
×

APPENDIX B
COST AND PROBABILITY ASSUMPTIONS USED IN COST-EFFECTIVENESS ANALYSIS OF PRENATAL HIV SCREENING

Category

HIV Negative on ELISA Test

HIV Positive or Indeterminate on ELISA Test

Laboratory

First ELISA

$5

 

Three ELISA tests

 

$10

Western Blot

 

$35

Risk assessmenta

$2

$ 2

Counseling

Pretest

$7

$ 7

Posttest

$1

$45

a For selective screening only.

Cost Assumptions

  1. All cost figures are estimates of average costs, in 1989 dollars, per person screened.

  2. The column ''HIV Negative on ELISA Test'' shows average costs for individuals screened who are negative on the ELISA and require no confirmatory Western Blot testing. This includes HIV-negative individuals who test negative on the first ELISA (the majority) and require no further testing. It also includes HIV-negative persons whose first ELISA is borderline reactive but whose two repeat ELISA tests run in duplicate on the same blood specimen are clearly negative.

Suggested Citation:"Appndix B: Cost and Probability Assumptions Used in Cost-Effectiveness Analysis of Prenatal HIV Screening." Institute of Medicine. 1991. HIV Screening of Pregnant Women and Newborns. Washington, DC: The National Academies Press. doi: 10.17226/1746.
×

According to blood donor screening data, about two-thirds of all initially positive ELISA results are negative on repeat.1

It is assumed that the blood sample for the HIV test is drawn with the standard prenatal panel after informed consent has been obtained. The average cost of $5 per person screened includes the estimated cost of the laboratory test and the cost of providing information that is sufficient for informed consent concerning the purpose, benefits, and risks of the HIV test.

  1. The column "HIV Positive or Indeterminate on ELISA Test" shows the average cost for individuals screened who require Western Blot testing. This includes those individuals who test positive on the first and two repeat ELISA tests. It also includes those who test positive on the first and one of the two repeat ELISA tests; some of these will yield a positive Western Blot result. Some will have a negative or indeterminate Western Blot and require further testing with additional blood specimens. The blood donor screening studies cited earlier have shown that about one-third of those testing positive on the first ELISA were persistently positive on the repeat ELISA, and 10 percent were also positive on the Western Blot. Of those repeatedly but weakly positive on the ELISA, only about 1 percent were positive on Western Blot testing.

  2. To estimate the average laboratory cost a telephone survey was conducted of manufacturers of the reagents and of several commercial and public laboratories in the San Francisco Bay area. Average cost estimates are based on information provided by large public laboratories where economies of scale occur both in terms of manufacturer discounts and in processing the specimens with adequate quality control.

  3. In selective screening, a risk assessment cost will be incurred for all women who present for prenatal care. It is assumed that risk assessment consists of a written instrument that will be part of an intake questionnaire. For most individuals this will be sufficient, although some women with risk factors may need further explanation in the course of the intake visit; the estimate is for average cost.

1  

 R. S. Eisenstaedt and T. F.. Getzen, "Screening Blood Donors for Human Immunodeficiency Virus Antibody: Cost-Benefit Analysis," American Journal of Public Health 78(1988):450-454; Irwin Memorial Blood Bank, unpublished data, 1989.

    Suggested Citation:"Appndix B: Cost and Probability Assumptions Used in Cost-Effectiveness Analysis of Prenatal HIV Screening." Institute of Medicine. 1991. HIV Screening of Pregnant Women and Newborns. Washington, DC: The National Academies Press. doi: 10.17226/1746.
    ×
    1. Under all screening strategies, universal as well as selective, all women who test HIV positive will receive specific HIV-related counseling. In selective screening, all women will receive specific HIV-related counseling, even if they test HIV negative, because all women screened have risk factors.

      In universal screening, the cost implications of providing specific HIV-related counseling to HIV-positive women only are compared with the costs of providing such counseling to all women screened.

    2. The lowest basic cost estimates for counseling have been used in the analysis because counseling is by far the most expensive item in the screening program cost. It was assumed that specific HIV-related pretest counseling would be added on to general pregnancy-related health counseling and would require a minimal marginal cost for most women who do not have risk factors. On the other hand, for some women with risk factors, the HIV-specific additional counseling would be more intensive. The analysis includes an estimated average pretest counseling cost of $7 per woman screened. It was also assumed that posttest counseling for HIV-negative women would consist of handing out an informative pamphlet about HIV prevention, which would be sufficient for most women. Some women who have known risk factors, however, may require specific information concerning risk reduction in their particular circumstances.

    Counseling for HIV-positive women is assumed to involve intensive posttest counseling, including information on the risk of transmission, prevention, and health care and reproductive options. The average cost of counseling has been estimated at $53; in the case of screening programs with counseling for all, this would include an average cost of $7 for pretest counseling.

    Probability Assumptions

    1. p(D/NoRF) = 0

      i.e., the probability of disease, given that there are no risk factors, is equal to 0; all HIV infection occurs in women with risk factors only.

      If, on the other hand, there is a nonzero background rate in women without risk factors, then selective screening will miss more than the assumed 50 percent of HIV-positive women.

      For example, if the background rate in women without risk factors is 0.0001 (the estimated probability of HIV infection in a U.S. adult without risk factors), then selective screening will miss about 6 HIV-

    Suggested Citation:"Appndix B: Cost and Probability Assumptions Used in Cost-Effectiveness Analysis of Prenatal HIV Screening." Institute of Medicine. 1991. HIV Screening of Pregnant Women and Newborns. Washington, DC: The National Academies Press. doi: 10.17226/1746.
    ×

    positive women per 100,000 women. At low overall prevalences, this means that selective screening can at best pick up only about a quarter of HIV-positive women rather than one-half.

    1. To calculate the prevalence of HIV infection among women with risk factors, the following identity has been used:

      p(D) = p(D/RF) × p(RF) + p(D/NoRF) × p(NoRF),

      where

    p(D)

    =

    the overall regional prevalence among childbearing women (from newborn screening data)

    p(D/RF)

    =

    the conditional probability of disease given risk factor(s)

    p(RF)

    =

    the estimated regional prevalence of risk factors among childbearing women (estimated to be 0.10 at baseline)

    p(D/NoRF)

    =

    the conditional probability of disease given no risk factor (estimated to be 0 in the present analysis, or 0.0001 in sensitivity analysis)

    p(NoRF)

    =

    1 minus the estimated regional prevalence of risk factors among childbearing women (estimated to be 0.90 at baseline)

    1. p(TEST) = p(TEST/HIV+)

      i.e., the probability of testing is equal to the probability of testing HIV-positive women.

      This is a severe restriction that tends to underestimate the cost of selective screening and overestimate the cost of universal screening:

    1. For selective screening, this means that 50 percent of HIV-positive women are identified when only 50 percent of the women with risk factors are tested.

      In reality, considerably more than 50 percent of the women may need to be tested in order to detect 50 percent of HIV-positive women. Thus, the cost per HIV-positive woman identified is considerably higher, as shown by sensitivity analysis.

    Suggested Citation:"Appndix B: Cost and Probability Assumptions Used in Cost-Effectiveness Analysis of Prenatal HIV Screening." Institute of Medicine. 1991. HIV Screening of Pregnant Women and Newborns. Washington, DC: The National Academies Press. doi: 10.17226/1746.
    ×
    1. For universal screening, this means that 95 percent of pregnant women would need to be tested in order to detect 95 percent of HIV-positive women.

      In reality, a much smaller proportion of the pregnant population may need to be tested. In some low-prevalence regions, many women may correctly assess themselves as having no risk, so that little is lost if they refuse testing.

    N.B.: If the goal is not only to detect the maximum number of HIV-positive women but also to counsel the maximum number of women at risk who are not yet infected, then the assumption concerning the prevalence of risk factors becomes crucial. Depending on that prevalence, universal screening with counseling for all may be advantageous even at a relatively low rate of infection in the region.

    Suggested Citation:"Appndix B: Cost and Probability Assumptions Used in Cost-Effectiveness Analysis of Prenatal HIV Screening." Institute of Medicine. 1991. HIV Screening of Pregnant Women and Newborns. Washington, DC: The National Academies Press. doi: 10.17226/1746.
    ×
    This page in the original is blank.
    Suggested Citation:"Appndix B: Cost and Probability Assumptions Used in Cost-Effectiveness Analysis of Prenatal HIV Screening." Institute of Medicine. 1991. HIV Screening of Pregnant Women and Newborns. Washington, DC: The National Academies Press. doi: 10.17226/1746.
    ×
    Page 129
    Suggested Citation:"Appndix B: Cost and Probability Assumptions Used in Cost-Effectiveness Analysis of Prenatal HIV Screening." Institute of Medicine. 1991. HIV Screening of Pregnant Women and Newborns. Washington, DC: The National Academies Press. doi: 10.17226/1746.
    ×
    Page 130
    Suggested Citation:"Appndix B: Cost and Probability Assumptions Used in Cost-Effectiveness Analysis of Prenatal HIV Screening." Institute of Medicine. 1991. HIV Screening of Pregnant Women and Newborns. Washington, DC: The National Academies Press. doi: 10.17226/1746.
    ×
    Page 131
    Suggested Citation:"Appndix B: Cost and Probability Assumptions Used in Cost-Effectiveness Analysis of Prenatal HIV Screening." Institute of Medicine. 1991. HIV Screening of Pregnant Women and Newborns. Washington, DC: The National Academies Press. doi: 10.17226/1746.
    ×
    Page 132
    Suggested Citation:"Appndix B: Cost and Probability Assumptions Used in Cost-Effectiveness Analysis of Prenatal HIV Screening." Institute of Medicine. 1991. HIV Screening of Pregnant Women and Newborns. Washington, DC: The National Academies Press. doi: 10.17226/1746.
    ×
    Page 133
    Suggested Citation:"Appndix B: Cost and Probability Assumptions Used in Cost-Effectiveness Analysis of Prenatal HIV Screening." Institute of Medicine. 1991. HIV Screening of Pregnant Women and Newborns. Washington, DC: The National Academies Press. doi: 10.17226/1746.
    ×
    Page 134
    Next: Appendix C: Cost Estimates: Early Intervention for HIV Infection »
    HIV Screening of Pregnant Women and Newborns Get This Book
    ×
    Buy Paperback | $50.00
    MyNAP members save 10% online.
    Login or Register to save!
    Download Free PDF

    Proposals for screening pregnant women and newborns for HIV infection have provoked much controversy. This volume analyzes the possible goals of such screening programs and assesses whether these goals can currently be achieved. It also provides guidance to policymakers in developing and implementing sound screening policy.

    1. ×

      Welcome to OpenBook!

      You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

      Do you want to take a quick tour of the OpenBook's features?

      No Thanks Take a Tour »
    2. ×

      Show this book's table of contents, where you can jump to any chapter by name.

      « Back Next »
    3. ×

      ...or use these buttons to go back to the previous chapter or skip to the next one.

      « Back Next »
    4. ×

      Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

      « Back Next »
    5. ×

      Switch between the Original Pages, where you can read the report as it appeared in print, and Text Pages for the web version, where you can highlight and search the text.

      « Back Next »
    6. ×

      To search the entire text of this book, type in your search term here and press Enter.

      « Back Next »
    7. ×

      Share a link to this book page on your preferred social network or via email.

      « Back Next »
    8. ×

      View our suggested citation for this chapter.

      « Back Next »
    9. ×

      Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

      « Back Next »
    Stay Connected!